Effect of rimonabant on weight reduction and cardiovascular risk

被引：16
作者：
Hirschel, B [1 ]
机构：
[1] Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva, Switzerland
来源：
LANCET | 2005年 / 366卷 / 9483期
关键词：
D O I：
10.1016/S0140-6736(05)67019-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：369 / 369
页数：1
相关论文
共 5 条
  • [1] Coxibs and cardiovascular disease
    FitzGerald, GA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (17) : 1709 - 1711
  • [2] COX-2 inhibitors - Lessons in drug safety
    Psaty, BM
    Furberg, CD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) : 1133 - 1135
  • [3] Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice
    Steffens, S
    Veillard, NR
    Arnaud, C
    Pelli, G
    Burger, F
    Staub, C
    Zimmer, A
    Frossard, JL
    Mach, F
    [J]. NATURE, 2005, 434 (7034) : 782 - 786
  • [4] Failing the public health - Rofecoxib, Merck, and the FDA
    Topol, EJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (17) : 1707 - 1709
  • [5] Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:: 1-year experience from the RIO-Europe study
    Van Gaal, LF
    Rissanen, AM
    Scheen, AJ
    Ziegler, O
    Rössner, S
    [J]. LANCET, 2005, 365 (9468) : 1389 - 1397
1